These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3834847)

  • 1. The activity of plumbagin and other electron carriers against Leishmania donovani and Leishmania mexicana amazonensis.
    Croft SL; Evans AT; Neal RA
    Ann Trop Med Parasitol; 1985 Dec; 79(6):651-3. PubMed ID: 3834847
    [No Abstract]   [Full Text] [Related]  

  • 2. Antileishmanial effects of clofazimine and other antimycobacterial agents.
    Evans AT; Croft SL; Peters W; Neal RA
    Ann Trop Med Parasitol; 1989 Oct; 83(5):447-54. PubMed ID: 2619361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voacamine alters Leishmania ultrastructure and kills parasite by poisoning unusual bi-subunit topoisomerase IB.
    Chowdhury SR; Kumar A; Godinho JLP; De Macedo Silva ST; Zuma AA; Saha S; Kumari N; Rodrigues JCF; Sundar S; Dujardin JC; Roy S; De Souza W; Mukhopadhyay S; Majumder HK
    Biochem Pharmacol; 2017 Aug; 138():19-30. PubMed ID: 28483460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
    Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
    Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.
    Zhu X; Farahat AA; Mattamana M; Joice A; Pandharkar T; Holt E; Banerjee M; Gragg JL; Hu L; Kumar A; Yang S; Wang MZ; Boykin DW; Werbovetz KA
    Bioorg Med Chem Lett; 2016 May; 26(10):2551-2556. PubMed ID: 27048943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel arylimidamides for treatment of visceral leishmaniasis.
    Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileishmanial activity of a naphthoquinone derivate against promastigote and amastigote stages of Leishmania infantum and Leishmania amazonensis and its mechanism of action against L. amazonensis species.
    Mendonça DVC; Lage DP; Calixto SL; Ottoni FM; Tavares GSV; Ludolf F; Chávez-Fumagalli MA; Schneider MS; Duarte MC; Tavares CAP; Alves RJ; Coimbra ES; Coelho EAF
    Parasitol Res; 2018 Feb; 117(2):391-403. PubMed ID: 29248978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis.
    Al-Abdely HM; Graybill JR; Bocanegra R; Najvar L; Montalbo E; Regen SL; Melby PC
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2542-8. PubMed ID: 9756753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.
    Lamotte S; Aulner N; Späth GF; Prina E
    Sci Rep; 2019 Jan; 9(1):438. PubMed ID: 30679614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.
    Freitas EO; Nico D; Guan R; Meyer-Fernandes JR; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS One; 2015; 10(4):e0124183. PubMed ID: 25909893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered transport properties of pentamidine-resistant Leishmania donovani and L. amazonensis promastigotes.
    Basselin M; Lawrence F; Robert-Gero M
    Parasitol Res; 1997; 83(5):413-8. PubMed ID: 9197387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activity of hydroxynaphthoquinones against Leishmania donovani.
    Croft SL; Hogg J; Gutteridge WE; Hudson AT; Randall AW
    J Antimicrob Chemother; 1992 Dec; 30(6):827-32. PubMed ID: 1289357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani.
    Petit C; Yardley V; Gaboriau F; Bolard J; Croft SL
    Antimicrob Agents Chemother; 1999 Feb; 43(2):390-2. PubMed ID: 9925541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).
    Yang M; Arai C; Bakar Md A; Lu J; Ge JF; Pudhom K; Takasu K; Kasai K; Kaiser M; Brun R; Yardley V; Itoh I; Ihara M
    J Med Chem; 2010 Jan; 53(1):368-73. PubMed ID: 19894726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil.
    Neal RA; van Bueren J; McCoy NG; Iwobi M
    Trans R Soc Trop Med Hyg; 1989; 83(2):197-8. PubMed ID: 2558433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perifosine Mechanisms of Action in Leishmania Species.
    López-Arencibia A; Martín-Navarro C; Sifaoui I; Reyes-Batlle M; Wagner C; Lorenzo-Morales J; Maciver SK; Piñero JE
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of medicinal plants against Leishmania amazonensis.
    García M; Monzote L; Montalvo AM; Scull R
    Pharm Biol; 2010 Sep; 48(9):1053-8. PubMed ID: 20731558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.